Europe Neuropathic Pain Market – Industry Trends and Forecast to 2028

  • Healthcare
  • Published Report
  • Jun 2021
  • Europe
  • 350 Pages
  • No of Tables: 258
  • No of Figures: 68

Europe Neuropathic Pain Market, By Type (Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (Tens) Devices), Product Type (Rechargeable and Non-Rechargeable), Procedure (Invasive and Non-Invasive), Technology (Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation), Modality (Stationary and Portable), Mode of Purchase (Over-the-Counter Devices and Prescription-Based Devices), Pain Type (Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain, Coccydynia), Indication (Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, Others), End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Third Party Distributor and Others), Country (Germany, France, U.K., Italy, Russia, Spain, Netherlands, Turkey, Switzerland, Rest of Europe) Industry Trends and Forecast To 2028     

Europe Neuropathic Pain Market Market Analysis and Insights: Europe Neuropathic Pain Market

The neuropathic pain market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.1% in the forecast period of 2021 to 2028 and is expected to reach USD 1,992.30 million by 2028. As these devices are long lasting and efficient which is the major driver boosting the demand of the neuropathic pain market in the forecast period. Growing prevalence of chronic pain and neuropathic pain condition associated with many diseases will act as a driver for the growth of the neuropathic pain market.

Neuropathic pain is caused by a lesion or disease of the somatosensory system including peripheral fibres (Aβ, Aδ and C fibres) and central neurons and affects 7–10% of the general population. Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the aging global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy.

Increasing R&D expenditure by various market players to create advanced products is expected to drive the growth of the neuropathic pain market. Limitation associated with the medical devices which limits the use of products is expected to act as restraint for the growth of the neuropathic pain market. High risk of neuropathic pain with ageing and rising older population in many countries will create an opportunity for the growth of the neuropathic pain market. Use of traditional therapies in emerging countries due to low health expenditure and disrupted supply chain is expected to act as a challenge for the growth of the neuropathic pain market.

The neuropathic pain market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.   

Europe Neuropathic Pain Market Neuropathic Pain Market Scope and Market Size

The neuropathic pain market is segmented on the basis of the type, product type, procedure, technology, modality, mode of purchase, pain type, indication, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

  • On the basis of type, the neuropathic pain market is segmented into spinal cord stimulation (SCS) devices, external peripheral nerve stimulation and transcutaneous electrical nerve stimulation (TENS) devices. In 2021, spinal cord stimulation (SCS) devices segment dominate the neuropathic pain market due to the vast usage of these devices for various neuropathic pain indications and the wide range of the products available in the market.
  • On the basis of product type, the neuropathic pain market is segmented into rechargeable and non-rechargeable. In 2021, the rechargeable segment is expected to show significant growth because rechargeable devices avoid the discharged battery's surgical replacement in traditional devices.
  • On the basis of procedure, the neuropathic pain market is segmented into invasive and non-invasive. In 2021, the invasive segment is expected to dominate the market because these devices available in the market are generally operating by invasive procedures that generally provide better efficiency for neuropathic pain.
  • On the basis of technology, the neuropathic pain market is segmented into transcutaneous electrical nerve stimulation, transcranial magnetic stimulation and respiratory electrical stimulation. In 2021, the transcutaneous electrical nerve stimulation segment is expected to show significant growth because transcutaneous electrical nerve stimulation is a non-invasive, inexpensive, self-administered technique to relieve pain due to the growing technological advancement, these devices are increasing their market size.
  • On the basis of modality, the neuropathic pain market is segmented into stationary and portable. In 2021, the stationary devices segment is expected to show significant growth rate due to rising incidences of chronic diseases such as cancer, cardiovascular, neurovascular disease and musculoskeletal diseases which generally include RF generators and other devices which are stationary in nature.
  • On the basis of mode of purchase, the neuropathic pain market is segmented into over-the-counter devices and prescription-based devices. In 2021, the prescription-based devices segment is expected to dominate the market due to the wide range of products available as = prescription-based devices increase the market share of the segment.
  • On the basis of pain type, the neuropathic pain market is segmented into peripheral neuropathy, entrapment neuropathy, phantom limb neuropathy, trigeminal neuralgia, post herpetic neuralgia, (PHN) post traumatic neuropathy, foot pain and coccydynia. In 2021, the peripheral neuropathy segment is expected to show the significant growth due to the increasing prevalence of peripheral neuropathy across the globe.
  • On the basis of indication, the neuropathic pain market is segmented into spinal stenosis, chemotherapy-induced peripheral neuropathy, diabetic neuropathy and others. In 2021, the diabetic neuropathy segment is likely to dominate the market due to the changing lifestyle pattern resulting in rising cases of diabetic patients at an early age.
  • On the basis of end user, the neuropathic pain market is segmented into hospitals, clinics, home healthcare, ambulatory surgical centers and others. In 2021, the hospitals segment is growing due to trained professionals as the hospitals department has a well-trained staffs with a professional team for proper and better treatment of the patients.
  • On the basis of distribution channel, the neuropathic pain market is segmented into direct tender, third party distributor and others. In 2021, direct tender segment accelerates the revenue growth and provides tax benefits owing to which the direct tender segment is flourishing for the last few years.

Europe Neuropathic Pain Market Country Level Analysis

Europe neuropathic pain market is analysed and market size information is provided by the country, type, product type, procedure, technology, modality, mode of purchase, pain type, indication, end user and distribution channel as referenced above.

The countries covered in the Europe neuropathic pain market report are the Germany, France, U.K., Italy, Russia, Spain, Netherlands, Turkey, Switzerland and rest of Europe.   

Europe is expected to grow with the significant growth rate in the forecast period of 2021 to 2028 due to more advancement and rise in demand for neuropathic pain devices. The U.K. is dominating in the Europe neuropathic pain market owing to the increasing cases of neuropathic pain in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Increasing Collaboration by the Players for Advanced Neuropathic Pain is Creating New Opportunities for Players in the Neuropathic Pain Market    

The neuropathic pain market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the neuropathic pain market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2019.

Competitive Landscape and Neuropathic Pain Market Share Analysis

The neuropathic pain market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Europe neuropathic pain market.

The major players covered in the Europe neuropathic pain market report are NEVRO CORP., Boston Scientific Corporation, Abbott, electroCore, Inc., Polar Medical, B. Braun Melsungen AG, Omron Healthcare, Inc., Cirtec, Medtronic and Integer Holdings Corporation and AVNS among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contracts and agreements are also initiated by the companies’ worldwide which are also accelerating the neuropathic pain market.

For instance,

  • In December 2021, Boston Scientific Corporation announced that they have launched WaveWriter Alpha Spinal Cord Stimulator Systems. This product is used for chronic pain and can be used in the neuropathic pain. This launch will add up to the revenue of the company and will gain the market share in the forecasted period.

Collaboration, joint ventures and other strategies by the market players is enhancing the company footprints in the neuropathic pain market which also provides the benefit for organisation in its growth pace.

Customization Available: Europe Neuropathic Pain Market  

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 EUROPE NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 2 EUROPE SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 3 EUROPE SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 4 EUROPE EXTERNAL PERIPHERAL NERVE STIMULATIONIN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 5 EUROPE EXTERNAL PERIPHERAL NERVE STIMULATIONIN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 6 EUROPE DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 7 EUROPE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 8 EUROPE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 9 EUROPE NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 10 EUROPE RECHARGEABLE IN NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 11 EUROPE NON-RECHARGEABLE NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 12 EUROPE NEUROPATHIC PAIN DEVICE MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 13 EUROPE NON-INVASIVE INVASIVE IN NEUROPATHIC PAIN DEVICE MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 14 EUROPE INVASIVE IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)

TABLE 15 EUROPE NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 16 EUROPE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 17 EUROPE TRANSCRANIAL MAGNETIC STIMULATION NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 18 EUROPE RESPIRATORY ELECTRICAL STIMULATION NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 19 EUROPE NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 20 EUROPE PORTABLE NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 21 EUROPE PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 22 EUROPE STATIONARY NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 23 EUROPE STATIONARY NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 24 EUROPE NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 25 EUROPE PRESCRIPTION-BASED DEVICES NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 26 EUROPE OVER-THE-COUNTER DEVICES NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 27 EUROPE NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 28 EUROPE PERIPHERAL NEUROPATHY NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 29 EUROPE PHANTOM LIMB PAIN NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 30 EUROPE POST HERPETIC NEURALGIA (PHN) NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 31 EUROPE POST TRAUMATIC NEUROPATHYNEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 32 EUROPE ENTRAPMENT NEUROPATHY NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 33 EUROPE FOOT PAIN NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 34 EUROPE TRIGEMINAL NEURALGIA NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 35 EUROPE COCCYDYNIA NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 36 EUROPE OTHERS NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 37 EUROPE NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 38 EUROPE SPINAL STENOSIS NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 39 EUROPE SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 40 EUROPE DIABETIC NEUROPATHY NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 41 EUROPE DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 42 EUROPE CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 43 EUROPE CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 44 EUROPE OTHERS NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 45 EUROPE NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 EUROPE CLINICS NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 47 EUROPE HOSPITALS NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 48 EUROPE HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 49 EUROPE HOME HEALTHCARE NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 50 EUROPE AMBULATORY SURGICAL CENTERS NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 51 EUROPE OTHERS NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 52 EUROPE NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 53 EUROPE DIRECT TENDERS NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 54 EUROPE THIRD PARTY DISTRIBUTION NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 55 EUROPE OTHERS NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 56 EUROPE NEUROPATHIC PAIN MARKET, BY REGION , 2021-2028 (USD MILLION)

TABLE 57 EUROPE NEUROPATHIC PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 58 EUROPE NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 59 EUROPE SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 60 EUROPE EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 61 EUROPE DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 62 EUROPE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 EUROPE NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 64 EUROPE NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 65 EUROPE NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 66 EUROPE NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 67 EUROPE STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 68 EUROPE PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 69 EUROPE NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 70 EUROPE NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 71 EUROPE NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 72 EUROPE SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 73 EUROPE CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 74 EUROPE DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 75 EUROPE NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 76 EUROPE HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 77 EUROPE NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 78 GERMANY NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 79 GERMANY SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 80 GERMANY EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 81 GERMANY DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 82 GERMANY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 83 GERMANY NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 84 GERMANY NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 85 GERMANY NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 86 GERMANY NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 87 GERMANY STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 88 GERMANY PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 89 GERMANY NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 90 GERMANY NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 91 GERMANY NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 92 GERMANY SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 93 GERMANY CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 94 GERMANY DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 95 GERMANY NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 96 GERMANY HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 97 GERMANY NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 98 FRANCE NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 99 FRANCE SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 100 FRANCE EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 101 FRANCE DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 FRANCE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 103 FRANCE NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 104 FRANCE NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 105 FRANCE NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 106 FRANCE NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 107 FRANCE STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 108 FRANCE PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 109 FRANCE NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 110 FRANCE NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 111 FRANCE NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 112 FRANCE SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 113 FRANCE CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 114 FRANCE DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 115 FRANCE NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 116 FRANCE HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 117 FRANCE NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 118 U.K. NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 119 U.K. SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 120 U.K. EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 121 U.K. DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 U.K. TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 123 U.K. NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 124 U.K. NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 125 U.K. NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 126 U.K. NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 127 U.K. STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 128 U.K. PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 129 U.K. NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 130 U.K. NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 131 U.K. NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 132 U.K. SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 133 U.K. CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 134 U.K. DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 135 U.K. NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 136 U.K. HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 137 U.K. NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 138 ITALY NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 139 ITALY SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 140 ITALY EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 141 ITALY DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 142 ITALY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 143 ITALY NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 144 ITALY NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 145 ITALY NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 146 ITALY NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 147 ITALY STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 148 ITALY PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 149 ITALY NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 150 ITALY NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 151 ITALY NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 152 ITALY SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 153 ITALY CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 154 ITALY DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 155 ITALY NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 156 ITALY HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 157 ITALY NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 158 RUSSIA NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 159 RUSSIA SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 160 RUSSIA EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 161 RUSSIA DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 162 RUSSIA TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 163 RUSSIA NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 164 RUSSIA NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 165 RUSSIA NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 166 RUSSIA NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 167 RUSSIA STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 168 RUSSIA PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 169 RUSSIA NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 170 RUSSIA NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 171 RUSSIA NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 172 RUSSIA SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 173 RUSSIA CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 174 RUSSIA DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 175 RUSSIA NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 176 RUSSIA HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 177 RUSSIA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 178 SPAIN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 179 SPAIN SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 180 SPAIN EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 181 SPAIN DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 182 SPAIN TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 183 SPAIN NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 184 SPAIN NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 185 SPAIN NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 186 SPAIN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 187 SPAIN STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 188 SPAIN PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 189 SPAIN NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 190 SPAIN NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 191 SPAIN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 192 SPAIN SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 193 SPAIN CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 194 SPAIN DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 195 RUSSIA NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 196 SPAIN HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 197 SPAIN NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 198 NETHERLANDS NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 199 NETHERLANDS SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 200 NETHERLANDS EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 201 NETHERLANDS DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 202 NETHERLANDS TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 203 NETHERLANDS NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 204 NETHERLANDS NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 205 NETHERLANDS NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 206 NETHERLANDS NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 207 NETHERLANDS STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 208 NETHERLANDS PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 209 NETHERLANDS NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 210 NETHERLANDS NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 211 NETHERLANDS NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 212 NETHERLANDS SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 213 NETHERLANDS CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 214 NETHERLANDS DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 215 NETHERLANDS NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 216 NETHERLANDS HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 217 NETHERLANDS NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 218 TURKEY NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 219 TURKEY SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 220 TURKEY EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 221 TURKEY DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 222 TURKEY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 223 TURKEY NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 224 TURKEY NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 225 TURKEY NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 226 TURKEY NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 227 TURKEY STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 228 TURKEY PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 229 TURKEY NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 230 TURKEY NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 231 TURKEY NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 232 TURKEY SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 233 TURKEY CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 234 TURKEY DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 235 TURKEY NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 236 TURKEY HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 237 TURKEY NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 238 SWITZERLAND NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 239 SWITZERLAND SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 240 SWITZERLAND EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 241 SWITZERLAND DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 242 SWITZERLAND TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 243 SWITZERLAND NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 244 SWITZERLAND NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 245 SWITZERLAND NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 246 SWITZERLAND NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 247 SWITZERLAND STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 248 SWITZERLAND PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 249 SWITZERLAND NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 250 SWITZERLAND NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 251 SWITZERLAND NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 252 SWITZERLAND SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 253 SWITZERLAND CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 254 SWITZERLAND DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 255 SWITZERLAND NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 256 SWITZERLAND HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 257 SWITZERLAND NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 258 REST OF EUROPE NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions